Abstract
IDH-mutant diffuse astrocytoma is a an infiltrative, slower-growing tumor that most commonly presents with seizures and is classically located in the frontal and temporal lobes. Diffuse astrocytomas tend to occur in younger patients when compared to malignant gliomas and are typically non-enhancing tumors on MRI. Today, most evidence leans towards earlier surgical intervention and if a complete resection is achieved in younger patients, further therapy can be safely deferred. In most other patients, there is a role for both radiation and chemotherapy. In this chapter, we discuss the evidence that is critical for clinicians to make these decisions as well as the practical approaches to treatment and toxicity management. Due to longer survival in these patients, long-term management of epilepsy and neurocognitive sequelae are critical.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kyritsis AP, Bondy ML, Rao JS, Sioka C. Inherited predisposition to glioma. Neuro Oncol. 2010;12:104–13.
Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.
Baumert BG, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: a randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). Lancet Oncol. 2016;17:1521–32.
Hasselblatt M, et al. Diffuse astrocytoma, IDH-wildtype: a dissolving diagnosis. J Neuropathol Exp Neurol. 2018;77:422–5.
Tesileanu CMS, et al. Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2019;22:515–23.
Pignatti BF, et al. Cerebral low-grade glioma. 2020;20:2076–2084.
Karim ABMF, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549–56.
Van Den Bent MJ, Witte D, Hassel MB. Long-term efficacy of early versus delayed radiotherapy for low-grade. Lancet. 2005;366:985–90.
Shaw E, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol. 2002;20:2267–76.
Karim ABMF, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52:316–24.
Laack NN, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys. 2005;63:1175–83.
Douw L, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–8.
Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in low- grade glioma. N Engl J Med. 2016;374:1344–55. https://doi.org/10.1016/j.physbeh.2017.03.040.
Darlix A, et al. Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. Neurooncol Pract. 2019;6:264–73.
Fisher BJ, Hu C, Macdonald DR, et al. Phase 2 study of Temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424. Int J Radiat Oncol Biol Phys. 2015;91:497–504. https://doi.org/10.1038/jid.2014.371.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low grade glioma. N Engl J Med. 2023;389:589–601.
Strowd RE, et al. Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. J Oncol Pharm Pract. 2013;19:321–7.
Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics. 2017;14:307–20.
Van Den Bent MJ, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985–90.
Chang EF, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults: clinical article. J Neurosurg. 2008;109:817–24.
Engloti DJ, Chang EG. Epilepsy and brain tumors. Handb Clin Neurol. 2016;134:267–85. https://doi.org/10.1016/j.physbeh.2017.03.040.
Ruda R, Bello L, Duffau H, et al. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012;14 Suppl 4(Suppl 4):iv55–64.
Boele FW, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. J Clin Oncol. 2015;33:1023–9.
Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet. 1991;337:1175–80.
Lossius MI, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus study). Epilepsia. 2008;49:455–63.
Vigliani MC, Sichez N, Poisson M, Delattre JY. A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys. 1996;35:527–33.
Noll KR, Ziu M, Weinberg JS, Wefel JS, Hospital S. Neurocognitive functioning in patients with glioma of the left and right temporal lobes. J Neurooncol. 2016;128:323–31.
Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16:2522–7.
Habets EJJ, et al. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J Neurooncol. 2014;116:161–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Molaie, D., Nghiemphu, P.(. (2023). Diffuse Astrocytoma. In: Mohile, N.A., Thomas, A.A. (eds) Brain Tumors. Springer, Cham. https://doi.org/10.1007/978-3-031-41413-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-031-41413-8_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-41412-1
Online ISBN: 978-3-031-41413-8
eBook Packages: MedicineMedicine (R0)